We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Single Hardware Solution Utilizes Multiple Diagnostics Technologies

By LabMedica International staff writers
Posted on 09 Sep 2010
A single hardware solution utilizes multiple diagnostics technologies such as enzyme immunoassay (EIA), chemiluminescence, and multiplexing.

Called the ThunderBolt platform, the inaugural product is an EIA processor, with a completely open software design capable of programming virtually any EIA test.

These tests are widely used to detect and quantify substances such as peptides, proteins, antibodies, and hormones, and to diagnose diseases and conditions including infections, cancer, metabolic disorders, allergies, and autoimmune diseases.

In a single, easily configured run, the flexible ThunderBolt EIA processor can process multiple microtiter plates, while also running up to eight different simultaneous assays. More...
With an onboard reader, the fully automated processor offers a true walkaway solution for labs of any size.

The compact design takes up less than half the workspace of similar EIA automated processors on the market. Cost-effective operation makes the platform suitable for larger clinical laboratories, while it also provides the customizable capabilities needed in hospital or research laboratories.

Gold Standard Diagnostics, Corp. (Davis, CA, USA), a provider of laboratory diagnostics solutions, introduced the ThunderBolt platform at the 2010 Clinical Lab Expo of the American Association for Clinical Chemistry (AACC), which was held at the Anaheim Convention Center (CA, USA) on July 25-29, 2010.

"The ThunderBolt platform represents a true innovation in automated diagnostics instrumentation and is the culmination of nearly 20 years of feedback from laboratory customers around the world,” says John Griffiths, president and CEO of Gold Standard Diagnostics. "By understanding what customers really need, we have been able to build a product that's the right blend of power, flexibility, and ease of use, all at a competitive price.”

GSD provides products, services, and consulting to the diagnostic and medical communities. The company has been creating and cost-effective diagnostics solutions for clinical and hospital laboratories since 2006.

Related Links:
Gold Standard Diagnostics, Corp.
American Association for Clinical Chemistry



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.